Net Sales in the Field. Vertex shall pay to CFFT the following royalties on annual Net Sales of each Drug Product: 4% [***] Net Sales [***] Net Sales [***] Net Sales [***] [***] Net Sales under this Section 5.3.1 shall not in any event include any Net Sales of Drug Products which are the subject of the royalty obligations set forth in Sections 5.3.2, 10.5.4, 10.5.5, and 10.5.6 hereof.
Appears in 3 contracts
Samples: Development and Commecialization Agreement (Royalty Pharma PLC), Research, Development and Commecialization Agreement (Royalty Pharma PLC), Development and Commecialization Agreement (Royalty Pharma PLC)
Net Sales in the Field. Vertex shall pay to CFFT the following royalties on annual Net Sales of each Drug Product: 4% [***] Net Sales [***] Net Sales [***] Net Sales [***] [***] Net Sales under this Section 5.3.1 shall not in any event include any Net Sales of Drug Products which are the subject of the royalty obligations set forth in Sections 5.3.2, 10.5.4, 10.5.5, and 10.5.6 hereof.
Appears in 2 contracts
Samples: Confidential Treatment Requested (Vertex Pharmaceuticals Inc / Ma), Development and Commecialization Agreement (Vertex Pharmaceuticals Inc / Ma)
Net Sales in the Field. Vertex shall pay to CFFT the following royalties on annual Net Sales of each Drug Product: 4% [***] Net Sales [***] Net Sales [***] Net Sales [***] [***] Net Sales under this Section 5.3.1 shall not in any event include any Net Sales of Drug Products which are the subject of the royalty obligations set forth in Sections 5.3.2, 10.5.4, 10.5.5, and 10.5.6 hereof. * Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Appears in 1 contract
Samples: Confidential Treatment Requested (Vertex Pharmaceuticals Inc / Ma)
